Background: The role of adiponectin in the development of cardiac disease remains less clear than in metabolic disorders. While some studies indicated that low adiponectin levels were associated with cardiovascular disease, not all studies have been able to show such association. Adiponectin levels may infl uence the development of chronic heart failure, but the epidemiological data are somewhat complex. Thus, the aim of this study was a survey of relationship between serum Adiponectin and prognosis of patients with heart failure in Iran.
Chronic heart failure (CHF) is a major cause of death and disability. Mortality rates approach 20 % per year despite current medical therapy (1) .
Obesity is a known risk factor for cardiovascular disease and for the development of chronic heart failure (CHF) (2) . However, recent data suggested that high body mass index (BMI) was associated with a more favorable prognosis in patients with established CHF (3-6).
Adipose tissue secretes a variety of biologically active molecules, including cytokines, growth factors and complement factors, into the systemic circulation (7) (8) (9) (10) (11) (12) .
Adiponectin is a 244 amino acid protein and the most abundant adipocytokine in adipose tissue (13) (14) . Plasma adiponectin concentrations are extremely high in healthy subjects and vary widely in several pathological states; for example, they decrease in obesity, diabetes mellitus, hypertension and other atherosclerotic disorders (15) (16) (17) (18) (19) (20) (21) (22) (23) .
Several features make adiponectin an attractive marker for cardiovascular risk. For example, plasma concentrations show little circadian variability, does not depend on fasting status, and shosw only a limited in-person variation over time (24) (25) (26) . In addition, because adiponectin circulates in relatively high concentrations in plasma, measurement of adiponectin needs only a limited amount of blood.
It is well known that various hormones, such as arginine vasopressin, cathecholamines and the reninangiotensin-aldosterone system, increase in concert with the severity of heart failure and they may be involved in the pathogenesis of heart failure. Also it is well-known that brain natriuretic peptide (BNP) increases with the severity of left ventricular dysfunction, and high values of BNP are associated with poor prognosis (27) .
The role of adiponectin in the development of cardiac disease remains less clear than in metabolic disorders. While some studies indicated that low adiponectin levels were associated with cardiovascular disease, not all studies have been able to show such association. For example, it has been reported that plasma adiponectin concentrations were lower in patients with clinical manifestations of coronary artery disease than in age and BMI-adjusted control subjects independent of other risk factors (28) (29) (30) . High plasma adiponectin levels were associated with a lower risk of myocardial infarction in men (31) . Collectively, these studies suggested that hypoadiponectinemia was associated with the development of cardiovascular diseases that are prevalent in obese individuals.
Finally, adiponectin levels may infl uence the development of chronic heart failure, but the epidemiological data are somewhat complex. Therefore, future studies should examine adiponectin levels in patients with stable heart failure.
Methods and materials
In this cohort study, we evaluated 96 chronic heart failure patients that referred to Shahid Beheshti and Vliasr hospitals in Zanjan since 2007 until 2009. Patients with systolic dysfunction that was defi ned as left ventricular Ejection Fraction (EF) ≤40 % by echocardiography (HDI 3500) or had a history of heart failure were included in the study. At the baseline visit, all patients were examined by a physician and the following information was obtained: medical history, physical examination, New York Heart Association (NYHA) classifi cation and the patients were divided into the four groups. Class I (Mild), no limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea (shortness of breath). Class II (Mild), slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea. Class III (Moderate), marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea. Class IV (Severe), unable to carry out physical activity without discomfort. Symptoms of cardiac insuffi ciency present at rest. If any physical activity is undertaken, discomfort is increased. All data were collected in questioners. Then patients were followed up for the median of 12 months. None of the participants was lost during the follow-up. The patients included in this study have been followed up with respect to mortality status and changes in functional capacity and frequency of hospital admission. All patients with renal failure with creatinine ≥3 mg/dl were excluded from this study. BMI (Body Mass Index) categories by the World Health Organization was used for classifi cation, so patients with BMI <25 kg/m 2 were considered normal weight and patients with BMI 25-29.9 kg/m 2 were considered over weight.
Laboratory measurements
After a minimum 8-hour overnight fast, venous blood was drawn into EDTA tubes and centrifuged at 4 °C and plasma was frozen at -70 °C until analyses of adiponectin, Pro BNP, creatinine and uric acid were performed.
Adiponectin was measured by ELISA (Enzyme Linked Immuno Sorbent Assay) method by Biovendor Co. Germany kits where the assay sensitivity (detection limit 0.15ng/ml) and specifity was 100 % and the intra-assay and inter-assay reproducibility were (4.2-6.7 %) and (7.6-9.5 %) respectively.
Pro BNP was measured by ECLIA (Electro Chemiluminescence Immun) method by Germany Elec sys 2010 Roche. The kit assay was sensitive (detection limit 5pg/ml) and the inter-assay reproducibility was 7.2 %.
Uric acid and creatinine were measured by XL-300 biochemistry (Erba Co. Germany).
Statistical analysis
All values were expressed as the mean ± one SD. Continuous variable was analyzed by the one-way ANOVA or the KruskalWallis test to compare the difference among the four groups. Comparisons between patient groups were performed with the independent T samples test and the Mann-Whitney U test, as appropriate. All values were 2 tailed and the probability value <0.05 was considered statistically signifi cant. The statistical software package SPSS version 14 was used for all analyses.
The study was approved by the local ethics committee of the Zanjan medical university and all patients signed a written informed consent. 
Results
Totally 96 patients (55 male and 41 female) were enrolled in the study. All demographic data are shown in the Table 1 .
There was a signifi cant relationship between the mean adiponectin and Pro BNP levels and the ejection fraction (p=0.003 and p=0.003 respectively). Higher levels of adiponectin and Pro BNP were associated with a lower ejection fraction (Tab. 2) and there were no such associations between creatinine and uric acid levels.
There was a signifi cant association between the functional capacity as assessed by NYHA class and the mean of adiponectin and uric acid, these means that higher levels of adiponectin and uric acid were associated with a higher functional class in patients with CHF (p=0.03 and p=0.04 respectively) . The demographic data demonstrated that there was no relation between different age groups and the mean of adiponectin and Pro BNP and creatinine and uric. There was no association between these parameters and frequencies of hospital admission. Subsequently, the relation between plasma levels of adiponectin and BMI was examined and there was no association between the two parameters.
Adiponectin levels in the non-ischemic group were higher than in the ischemic group and this difference was statistically signifi cant (p=0.001). During the 12 month follow-up, 22 (22.9 %) patients died. In subjects who died, the baseline mean plasma adiponectin and Pro BNP levels were higher compared to those who were alive at the follow-up and these difference were statistically signifi cant (19±7.4 vs15.8±8 ng/ml and 9520±10249 vs 3172±4628 ng/L p=0.000) (Tab. 3).
Discussion
The present study demonstrated that the plasma adiponectin level increased according to the severity of heart failure and that there was such relationship between Pro BNP and heart failure. Recently Kistorp et al reported that the plasma level of adiponectin and N-terminal Pro BNP was a risk marker of CHF severity and predictor of mortality (32) , what was consistent with our study. There was no association between adiponectin and Pro BNP and frequency of hospital admission. Pocock SJ et al showed that there was 21 predictor variables for cardiovascular death and heart failure hospitalization, the three most powerful predictors were higher age (beginning >60 years), diabetes and lower left ventricular ejection fraction beginning <45 %) (33) . Adiponectin may infl uence the development of CHF, but the epidemiological data are scarce. Plasma levels of adiponectin are decreased in patients with ischemic heart disease but increased in patients with heart failure. The source of increased adiponectin levels in patients with CHF remains unknown. Takano H et al showed that adiponectin levels were signifi cantly higher in patients with either non-ischemic CHF or ischemic CHF than controls; the levels were similar between patients with non-ischemic CHF and those with ischemic CHF (34) , but in our study, adiponectin levels in the non-ischemic group were higher than in the ischemic group. In our study, adiponectin and Pro BNP levels were very useful in survival determination. This means that the mean Pro BNP and adiponectin levels were different between alive and dead patients and this difference was statistically signifi cant. This fi nding is in accordance with previous reports on survival analyses, which demonstrated that high adiponectin levels were associated with an increased mortality risk and patients with circulating adiponectin levels in the 2 upper tertiles had a 3-fold increased risk of mortality compared to those in the lowest tertiles (32) .
This fi nding could be counterintuitive, because adiponectin has been described to have anti infl ammatory and anti atherogenic properties. Epson H et al showed that adiponectin levels were signifi cantly increased in heart failure patients older than 70 years as compared to control group (35), but our study did not show such association. However, in their study, there were higher adiponectin levels in the non-ischemic heart failure as compared to those with ischemic causes and there was a strong trend of higher adiponectin levels in those who died as compared to those who survived and all of these were consistent with our results.
There are some limitations in our study: fi rst; we did not measure changes in weight or Pro BNP and adiponectin levels during the follow up. Second; we had a small sample size and also small number of deaths. Third; we did not have cut off point for adiponectin and Pro BNP in our healthy population.
However, this is the fi rst study that evaluated the relationship between adiponectin and prognosis of heart failure in our country and we suggested a larger study with a longer follow-up period.
